#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Intracranial germ cell tumour Uterine leiomyosarcoma Stevens-Johnson syndrome Thrombocytopenia Blastic plasmacytoid dendritic cell neoplasia Parkinson's disease Partial lipodystrophy Chordoma Andersen-Tawil syndrome Gastrointestinal disorder Thrombotic thrombocytopenic purpura Liver transplant rejection Fabry's disease B precursor type acute leukaemia Erythema More trials…

    Learn about Rare Diseases

    Ehlers-Danlos syndrome – Diagnostics Pleural mesothelioma malignant – Treatment Pulmonary sarcoidosis – Basic Information Gaucher’s disease type I – Trials in Disease CADASIL – Basic Information Antithrombin III deficiency – Basic Information Pulmonary sarcoidosis Mantle cell lymphoma stage II – Life with Disease Phenylketonuria – Treatment X-linked lymphoproliferative syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Docetaxel Teverelix Nipocalimab Salbutamol Sulfate Ph. Eur. Orismilast Chlorphenamine Glutenin Oxybutynin Fosinopril Sodium Citalopram Hydrobromide VTX2735 SODIUM HSP-CAR30 Levocarnitine Ondansetron Hydrochloride Iopromide Ulotaront Carboplatin MB-CART2219.1 Pegfilgrastim Ladarixin More therapies…

    Learn about Your Condition

    Brain stem glioma Gaucher's disease type I Advanced systemic mastocytosis Immune-mediated myositis Non-small cell lung cancer Diabetic foot infection Chronic granulomatous disease Ependymoma Skin disorder Epileptic encephalopathy Hot flush Prader-Willi syndrome Hepatic adenoma Tetanus Ocular melanoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Hospital Universitari General De Catalunya

Hospital Universitari General De Catalunya

Carrer Pedro I Pons 1, Sant Cugat Del Valles, 08195, Spain

Want to learn more about this study or check if you can participate? Contact us.

  • Study on the Effects of Gemlapodect for Adults and Adolescents with Tourette Syndrome

    Not recruiting

    2 1
    Investigated Drugs:
    • Gemlapodect
    Belgium France Germany Hungary Poland Spain

  • Study Comparing DB-1303 and Chemotherapy for Patients with HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive breast cancer
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Db-1303
    • Capecitabine
    • Paclitaxel
    Belgium France Germany Hungary Italy Poland +1

  • Study of RO7269162 in people at risk for or with early-stage Alzheimer’s Disease: Effects on brain amyloid buildup

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Prodromal Alzheimer’s disease
    Investigated Drugs:
    • Florbetaben (18F)
    • Flutemetamol (18F)
    • Ro7269162
    Denmark France Germany Italy Poland Spain

  • Study on the Effectiveness and Safety of ND0612 Infusion vs. Oral Treatment for Parkinson’s Disease Patients with Motor Fluctuations

    Not recruiting

    3 1
    Investigated Diseases:
    • Parkinson’s disease
    Investigated Drugs:
    • Carbidopa
    • Levodopa
    Austria Belgium Czechia France Italy Poland +3

  • Study on the Effectiveness and Safety of BIIB122 for Patients with Parkinson’s Disease

    Not recruiting

    2 1
    Investigated Diseases:
    • Parkinson’s disease
    Investigated Drugs:
    • N2-(3-(2-(2H-1,2,3-Triazol-2-Yl)Propan-2-Yl)-1-Cyclopropyl-1H-Pyrazol-5-Yl)-N4-Ethyl-5-(Trifluoromethyl)Pyrimidine-2,4-Diamine
    Austria France Germany Italy The Netherlands Poland +1

  • Study on the Long-Term Safety of Tavapadon for Patients with Parkinson’s Disease

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Parkinson’s disease
    Investigated Drugs:
    • Tavapadon
    Bulgaria Czechia France Germany Hungary Italy +2

  • Study to Improve Tolerance of Sacituzumab Govitecan with Loperamide and Filgrastim in Patients with Advanced Triple-Negative or Luminal Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone receptor positive breast cancer
    • Triple negative breast cancer
    Investigated Drugs:
    • Filgrastim
    • Loperamide Hydrochloride
    • Sacituzumab Govitecan
    Spain

  • Study on the Effectiveness and Safety of Batoclimab for Adults with Generalized Myasthenia Gravis

    Not recruiting

    3 1
    Investigated Diseases:
    • Myasthenia gravis
    Investigated Drugs:
    • Batoclimab
    Germany Hungary Italy Poland Romania Spain

  • Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with High-Risk HER2-Positive Breast Cancer with Residual Disease After Initial Treatment

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • HER2 positive breast cancer
    Investigated Drugs:
    • Trastuzumab Deruxtecan
    • Trastuzumab Emtansine
    Belgium Czechia Denmark France Germany Greece +7

  • Study on the Effectiveness and Safety of Ranibizumab for Patients with Wet Age-Related Macular Degeneration Using a 36-Week Refill System

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Age-related macular degeneration
    Investigated Drugs:
    • Ranibizumab
    Austria Belgium France Germany Italy Spain
Previous Page
1 … 4 5 6 7 8
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!